GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹6,376 Cr | ₹5,967 Cr | ₹5,819 Cr | ₹4,546 Cr | ₹4,689 Cr |
What is the latest Total Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹6,376 Cr |
| Mar2025 | ₹5,967 Cr |
| Mar2024 | ₹5,819 Cr |
| Mar2023 | ₹4,546 Cr |
| Mar2022 | ₹4,689 Cr |
How is Total Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹6,376 Cr | 6.86 | |
| Mar2025 | ₹5,967 Cr | 2.55 | |
| Mar2024 | ₹5,819 Cr | 27.99 | |
| Mar2023 | ₹4,546 Cr | -3.05 | |
| Mar2022 | ₹4,689 Cr | - | |
Compare Total Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹64,659.1 Cr | 0.4% | -7.5% | 11.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹421,539.0 Cr | -1.4% | -6.6% | 7.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹247,576.0 Cr | 1.2% | -2.6% | 60% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹177,251.0 Cr | -2% | -6.1% | 33% | Stock Analytics | |
| CIPLA | ₹105,290.0 Cr | -2.3% | -5.8% | -13.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,752.6 Cr | -1.1% | 3.8% | -5.5% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 0.4% |
-7.5% |
11.7% |
| SENSEX | 0.8% |
-4.8% |
-10.5% |
You may also like the below Video Courses